StockPriceToday
Fortrea Holdings Inc. (FTRE)
About Fortrea Holdings Inc.
Fortrea Holdings Inc. was established as an independent contract research organization following its spin-off from Labcorp in 2023, bringing decades of clinical development expertise to serve biopharmaceutical clients. The company has built comprehensive capabilities spanning early-stage clinical trials through late-stage development and regulatory approval processes. Fortrea has successfully established itself as a trusted partner for pharmaceutical and biotechnology companies seeking to accelerate drug development timelines. FTRE stock price performance reflects the company's position in the growing CRO market and its ability to secure long-term client partnerships.
The leadership team at Fortrea Holdings combines extensive experience in clinical research, regulatory affairs, and biopharmaceutical services. Management has successfully built a global organization with operations spanning multiple continents and therapeutic areas. The executive team's focus on scientific expertise, operational excellence, and client relationships has established Fortrea as a competitive player in the CRO industry. FTRE stock price movements often correlate with management's ability to win new business, execute complex clinical trials, and expand service capabilities across therapeutic areas.
Fortrea Holdings operates through a comprehensive platform that provides clinical development services including trial design, patient recruitment, data management, and regulatory support for biopharmaceutical clients. The company's capabilities serve various therapeutic areas and development stages while leveraging technology and global infrastructure to improve trial efficiency. Their business model generates revenue through service fees, milestone payments, and long-term partnership agreements with pharmaceutical and biotechnology companies. Investors evaluate factors such as clinical trial market growth, client concentration, competitive positioning, and pipeline of potential studies when assessing the company's long-term growth prospects and investment attractiveness.
FTRE Stock 12 Month Chart
Latest News for FTRE
Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Shares of clinical research company Fortrea Holdings ...
Fortrea Holdings (NASDAQ:FTRE) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...
Other Popular Stocks
Eastern Bankshares Inc. (EBC) is a bank holding company that operates Eastern Bank, providing commercial and consumer banking services throughout Massachusetts and neighboring New...
Angi Inc. operates digital marketplaces connecting homeowners with service professionals for home improvement and maintenance projects.
Calamos Dynamic Convertible & Income Fund is a closed-end fund investing in convertible securities and other income-producing investments.